Myeloid immune-checkpoint inhibition enters the clinical stage

Timo K van den Berg; Thomas Valerius

doi:10.1038/s41571-018-0155-3

Myeloid immune-checkpoint inhibition enters the clinical stage

Timo K van den Berg
, Thomas Valerius

Department of Immunology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
Division of Stem Cell Transplantation and Immunotherapy, Kiel, Germany

Research output: Contribution to journal › Article › Academic › peer-review

24 Downloads (Pure)

Abstract

The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.

Original language	English
Pages (from-to)	275-276
Journal	Nature reviews. Clinical oncology
Volume	16
Issue number	5
Early online date	20 Dec 2018
DOIs	https://doi.org/10.1038/s41571-018-0155-3
Publication status	Published - 1 May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41571-018-0155-3

Myeloid-immune-checkpoint-inhibition-enters-the-clinical-stage.pdfFinal published version, 599 KBLicence: Taverne

Cite this

@article{604a64ffe4e44d37a531cdc2dd1464d4,

title = "Myeloid immune-checkpoint inhibition enters the clinical stage",

abstract = "The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.",

author = "\{van den Berg\}, \{Timo K\} and Thomas Valerius",

year = "2019",

month = may,

day = "1",

doi = "10.1038/s41571-018-0155-3",

language = "English",

volume = "16",

pages = "275--276",

journal = "Nature reviews. Clinical oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Myeloid immune-checkpoint inhibition enters the clinical stage

AU - van den Berg, Timo K

AU - Valerius, Thomas

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.

AB - The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy.

UR - https://www.scopus.com/pages/publications/85058965272

UR - https://www.ncbi.nlm.nih.gov/pubmed/30573788

U2 - 10.1038/s41571-018-0155-3

DO - 10.1038/s41571-018-0155-3

M3 - Article

C2 - 30573788

SN - 1759-4774

VL - 16

SP - 275

EP - 276

JO - Nature reviews. Clinical oncology

JF - Nature reviews. Clinical oncology

IS - 5

ER -

Myeloid immune-checkpoint inhibition enters the clinical stage

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this